Zai Lab (ZLAB) Cost of Revenue (2019 - 2026)
Zai Lab (ZLAB) posted Cost of Revenue of $38.3 million for Q1 2026, down 38.5% sequentially from $62.3 million in Q4 2025, and little changed YoY from $38.5 million in Q1 2025.
Analysis
Zai Lab (ZLAB) Cost of Revenue (2019 - 2026) Analysis & Trends
Zai Lab has reported Cost of Revenue for 8 years, with the latest figure at $38.3 million in Q1 2026.
- Quarterly Cost of Revenue changed 0.36% year-over-year to $38.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $190.4 million (up 25.29% YoY) and the FY2025 annual result came in at $190.5 million, up 29.5% from the prior year.
- Cost of Revenue fell to $38.3 million in Q1 2026 per ZLAB's latest filing, from $62.3 million in the prior quarter.
- Over five years, Cost of Revenue peaked at $62.3 million in Q4 2025 and troughed at $15.6 million in Q1 2022.
- A 5-year average of $32.1 million and a median of $33.6 million in 2024 frame the typical range for Cost of Revenue.
- The widest YoY moves for Cost of Revenue: up 108.43% in 2022, down 3.59% in 2022.
- Over 5 years, Cost of Revenue stood at $20.9 million in 2022, then grew by 20.61% to $25.2 million in 2023, then surged by 65.56% to $41.8 million in 2024, then soared by 49.11% to $62.3 million in 2025, then sank by 38.5% to $38.3 million in 2026.
- According to Business Quant data, Cost of Revenue over the past three periods registered $38.3 million, $62.3 million, and $46.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 93.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 174.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 298.26 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Zai Lab | 2.92 Bn | 2.21 Bn | 58.15 Mn | 48.16 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 48.16 Mn |
| Mar 31, 2026 | 38.32 Mn |
| Dec 31, 2025 | 62.30 Mn |
| Sep 30, 2025 | 46.76 Mn |
| Jun 30, 2025 | 43.00 Mn |
| Mar 31, 2025 | 38.45 Mn |
| Dec 31, 2024 | 41.78 Mn |
| Sep 30, 2024 | 36.57 Mn |
| Jun 30, 2024 | 35.15 Mn |
| Mar 31, 2024 | 33.62 Mn |
| Dec 31, 2023 | 25.24 Mn |
| Sep 30, 2023 | 25.48 Mn |
| Jun 30, 2023 | 23.76 Mn |
| Mar 31, 2023 | 21.34 Mn |
| Dec 31, 2022 | 20.92 Mn |
| Sep 30, 2022 | 20.04 Mn |
| Jun 30, 2022 | 17.41 Mn |
| Mar 31, 2022 | 15.64 Mn |
| Dec 31, 2021 | 21.70 Mn |
| Sep 30, 2021 | 12.16 Mn |